专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060167247A1 Urea inhibitors of MAP kinases 失效
标题翻译： MAP激酶的尿素抑制剂
公开(公告)号：US20060167247A1
公开(公告)日：2006-07-27
申请号：US11295638
申请日：2005-12-07
申请人： Enrique Michelotti , Eric Springman , Duyan Nguyen , Rupa Shetty , Younghee Lee , Kristofer Moffett , Jennifer Ludington , Ted Fujimoto , Zenon Konteatis , Bin Liu , Frank Hollinger , Bruce Dorsey
发明人： Enrique Michelotti , Eric Springman , Duyan Nguyen , Rupa Shetty , Younghee Lee , Kristofer Moffett , Jennifer Ludington , Ted Fujimoto , Zenon Konteatis , Bin Liu , Frank Hollinger , Bruce Dorsey
IPC分类号： C07D417/02 , C07D413/02 , C07D409/02
CPC分类号： C07D333/38 , C07D231/40 , C07D243/08 , C07D277/48 , C07D277/56 , C07D295/192 , C07D333/36 , C07D403/06 , C07D405/06 , C07D409/04 , C07D409/06 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/06 , C07D417/14 , C07D495/04
摘要： The present invention is directed to a compound having the formula wherein R1, R2, G, and Q are defined herein. The compounds of the present invention are useful as inhibitors of protein kinases such as MAP kinases, in particular p38 kinases. The present invention is also directed to compositions comprising a compound according to the above formula. The compounds and compositions described herein are useful for treating and preventing an inflammatory condition or disease. The present invention is also directed to a method of treating or preventing a protein kinase-mediated condition.
摘要翻译：本发明涉及具有下式的化合物：其中R 1，R 2，G和Q在本文中定义。本发明的化合物可用作蛋白激酶如MAP激酶，特别是p38激酶的抑制剂。本发明还涉及包含根据上式的化合物的组合物。本文所述的化合物和组合物可用于治疗和预防炎性疾病或疾病。本发明还涉及治疗或预防蛋白激酶介导的病症的方法。

2. 发明授权

US07741479B2 Urea inhibitors of MAP kinases 失效
标题翻译： MAP激酶的尿素抑制剂
公开(公告)号：US07741479B2
公开(公告)日：2010-06-22
申请号：US11295638
申请日：2005-12-07
申请人： Enrique Luis Michelotti , Eric Bruce Springman , Duyan Nguyen , Rupa S. Shetty , Younghee Lee , Kristofer Kent Moffett , Jennifer Lee Ludington , Ted Tsutomis Fujimoto , Zenon D. Konteatis , Bin Liu , Frank Hollinger , Bruce D. Dorsey
发明人： Enrique Luis Michelotti , Eric Bruce Springman , Duyan Nguyen , Rupa S. Shetty , Younghee Lee , Kristofer Kent Moffett , Jennifer Lee Ludington , Ted Tsutomis Fujimoto , Zenon D. Konteatis , Bin Liu , Frank Hollinger , Bruce D. Dorsey
IPC分类号： C07D273/06
CPC分类号： C07D333/38 , C07D231/40 , C07D243/08 , C07D277/48 , C07D277/56 , C07D295/192 , C07D333/36 , C07D403/06 , C07D405/06 , C07D409/04 , C07D409/06 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/06 , C07D417/14 , C07D495/04
摘要： The present invention is directed to a compound having the formula wherein R1, R2, G, and Q are defined herein. The compounds of the present invention are useful as inhibitors of protein kinases such as MAP kinases, in particular p38 kinases. The present invention is also directed to compositions comprising a compound according to the above formula. The compounds and compositions described herein are useful for treating and preventing an inflammatory condition or disease. The present invention is also directed to a method of treating or preventing a protein kinase-mediated condition.
摘要翻译：本发明涉及具有下式的化合物：其中R1，R2，G和Q如本文所定义。本发明的化合物可用作蛋白激酶如MAP激酶，特别是p38激酶的抑制剂。本发明还涉及包含根据上式的化合物的组合物。本文所述的化合物和组合物可用于治疗和预防炎性疾病或疾病。本发明还涉及治疗或预防蛋白激酶介导的病症的方法。

3. 发明申请

US20060270686A1 Anti-cancer agents and uses thereof 失效
标题翻译：抗癌剂及其用途
公开(公告)号：US20060270686A1
公开(公告)日：2006-11-30
申请号：US10928401
申请日：2004-08-30
申请人： Martha Kelly , Younghee Lee , Bin Liu , Ted Fujimoto , Joel Freundlich , Bruce Dorsey , Gary Flynn , Arifa Husain
发明人： Martha Kelly , Younghee Lee , Bin Liu , Ted Fujimoto , Joel Freundlich , Bruce Dorsey , Gary Flynn , Arifa Husain
IPC分类号： A61K31/497 , A61K31/44 , C07D403/02
CPC分类号： C07D209/08 , C07D213/74 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/10 , C07D403/12 , C07D405/10 , C07D405/12 , C07D409/12 , C07D409/14 , C07D417/10
摘要： The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents. The compounds include compounds of Formula I: and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A1 is N or CR1; A3 is N or CR3; A5 is N or CR5; R1, R3—R6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6-10 carbons in the ring portion, an optionally-substituted 6-membered heteroaryl group having 1-3 nitrogen atoms in the ring portion, an optionally-substituted 5-membered heteroaryl group having 0-4 nitrogen atoms in the ring portion and optionally having 1 sulfur atom or 1 oxygen atom in the ring portion, or an optionally-substituted heteroaryl group in which a 6-membered ring is fused either to a 5-membered ring or to a 6-membered ring, wherein in each case 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulfur. They are effective against a broad range of cancers, especially leukemia, non-small cell lung and colon.
摘要翻译：本发明涉及新型化合物及其盐，其合成及其作为抗癌剂的用途。化合物包括式I化合物及其溶剂合物，水合物及其药学上可接受的盐，其中A 1是N或CR 1; N 3或N 3是N或CR 3; A <5>为N或CR 5; 在说明书中定义了R 1，R 3，R 6和L 6; n为0或1; 并且X是在环部分中具有6-10个碳的任选取代的芳基，在环部分中具有1-3个氮原子的任选取代的6元杂芳基，任选取代的5元杂芳基具有0 -4个氮原子，并且在环部分中任选具有1个硫原子或1个氧原子，或任选取代的杂芳基，其中6元环稠合到5元环或6元环其中在每种情况下，1,2,3或4个环原子是独立地选自氮，氧和硫的杂原子。它们对广泛的癌症尤其是白血病，非小细胞肺和结肠有效。

4. 发明申请

US20100041642A1 UREA INHIBITORS OF MAP KINASES 审中-公开
标题翻译：地图动物的尿素抑制剂
公开(公告)号：US20100041642A1
公开(公告)日：2010-02-18
申请号：US12541922
申请日：2009-08-15
申请人： Duyan NGUYEN , Martha KELLY , Kristofer MOFFETT , Enrique Luis MICHELOTTI , Bin Liu
发明人： Duyan NGUYEN , Martha KELLY , Kristofer MOFFETT , Enrique Luis MICHELOTTI , Bin Liu
IPC分类号： A61K31/496 , C07D409/14 , C07D413/14 , A61K31/5377 , A61K31/551 , A61P43/00
CPC分类号： C07D417/14 , C07D401/12 , C07D405/14 , C07D409/06 , C07D409/12 , C07D409/14 , C07D413/14 , C07D495/04
摘要： Urea containing compounds that inhibit MAP kinases, pharmaceutical compositions including such compounds and methods for using these compounds to treat inflammatory diseases and cancer are described herein.
摘要翻译：本文描述了抑制MAP激酶的含尿素化合物，包含这些化合物的药物组合物和使用这些化合物治疗炎性疾病和癌症的方法。

5. 发明申请

US20080280891A1 Anti-cancer agents and uses thereof 审中-公开
标题翻译：抗癌剂及其用途
公开(公告)号：US20080280891A1
公开(公告)日：2008-11-13
申请号：US11819494
申请日：2007-06-27
申请人： Martha Kelly , Younghee Lee , Bin Liu , Ted Fujimoto , Joel Freundlich , Bruce D. Dorsey , Gary A. Flynn , Arifa Husain , William R. Moore, Jr.
发明人： Martha Kelly , Younghee Lee , Bin Liu , Ted Fujimoto , Joel Freundlich , Bruce D. Dorsey , Gary A. Flynn , Arifa Husain , William R. Moore, Jr.
IPC分类号： A61K31/541 , A61K31/404 , C07D209/42 , C07D401/02 , C07D417/14 , A61K31/44 , A61P35/00 , A61K31/4439 , A61K31/5377 , C07D413/14
CPC分类号： A61K31/404 , A61K31/44 , A61K31/4439 , A61K31/5377 , A61K31/541 , C07D213/74 , C07D231/56 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D409/10 , C07D413/12 , C07D498/04
摘要： The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents. The compounds include compounds of Formula I: and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A1 is N or CR1; A3 is N or CR3; A5 is N or CR5; R1, R3-R6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6-10 carbons in the ring portion, an optionally-substituted 6-membered heteroaryl group having 1-3 nitrogen atoms in the ring portion, an optionally-substituted 5-membered heteroaryl group having 0-4 nitrogen atoms in the ring portion and optionally having 1 sulfur atom or 1 oxygen atom in the ring portion, or an optionally-substituted heteroaryl group in which a 6-membered ring is fused either to a 5-membered ring or to a 6-membered ring, wherein in each case 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulfur. They are effective against a broad range of cancers, especially leukemia, prostate, non-small cell lung and colon. They are additionally useful in the treatment of proliferative retinopathies such as diabetic neuropathy and macular degeneration.
摘要翻译：本发明涉及新型化合物及其盐，其合成及其作为抗癌剂的用途。化合物包括式I化合物及其溶剂合物，水合物及其药学上可接受的盐，其中A 1是N或CR 1; N 3或N 3是N或CR 3; A <5>为N或CR 5; 在说明书中定义了R 1，R 3，R 6和L 6; n为0或1; 并且X是在环部分中具有6-10个碳的任选取代的芳基，在环部分中具有1-3个氮原子的任选取代的6元杂芳基，任选取代的5元杂芳基具有0 -4个氮原子，并且在环部分中任选具有1个硫原子或1个氧原子，或任选取代的杂芳基，其中6元环稠合到5元环或6元环其中在每种情况下，1,2,3或4个环原子是独立地选自氮，氧和硫的杂原子。它们对广泛的癌症尤其是白血病，前列腺，非小细胞肺和结肠有效。它们还可用于治疗增殖性视网膜病变，例如糖尿病性神经病变和黄斑变性。

6. 发明授权

US08962623B2 Aminopyrazine compounds 有权
标题翻译：氨基吡嗪化合物
公开(公告)号：US08962623B2
公开(公告)日：2015-02-24
申请号：US14001936
申请日：2012-02-29
申请人： Rupa S. Shetty , Martha J. Kelly , Bin Liu , Jinming Zou , Kristofer K. Moffett , Younghee Lee , Dora Do-York Wong
发明人： Rupa S. Shetty , Kevin J. Moriarity , Martha J. Kelly , Bin Liu , Jinming Zou , Kristofer K. Moffett , Younghee Lee
IPC分类号： A61K31/5377 , C07D487/04 , C07D491/056 , C07D401/12 , C07D413/14 , C07D403/12 , C07D401/14 , C07D407/14 , C07D409/14 , C07D417/14
CPC分类号： C07D413/14 , C07D401/12 , C07D401/14 , C07D403/12 , C07D407/14 , C07D409/14 , C07D417/14 , C07D487/04 , C07D491/056
摘要： A compound of formula (I): wherein all symbols have the same meanings as defined in the specification; a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug thereof, has an Itk inhibitory activity, and is useful as a method for preventing and/or treating atopic dermatitis, and the like.
摘要翻译：式（I）的化合物：其中所有符号具有与说明书中定义的相同的含义; 其盐，其溶剂合物，N-氧化物或其前药具有Itk抑制活性，可用作预防和/或治疗特应性皮炎等的方法。

7. 发明申请

US20140187529A1 AMINOPYRAZINE COMPOUNDS 有权
标题翻译：氨基吡嗪化合物
公开(公告)号：US20140187529A1
公开(公告)日：2014-07-03
申请号：US14001936
申请日：2012-02-29
申请人： Rupa S. Shetty , Martha J. Kelly , Bin Liu , Jinming Zou , Kristopher K. Moffett , Younghee Lee
发明人： Rupa S. Shetty , Kevin J. Moriarity , Martha J. Kelly , Bin Liu , Jinming Zou , Kristopher K. Moffett , Younghee Lee
IPC分类号： C07D413/14 , C07D401/12 , C07D401/14
CPC分类号： C07D413/14 , C07D401/12 , C07D401/14 , C07D403/12 , C07D407/14 , C07D409/14 , C07D417/14 , C07D487/04 , C07D491/056
摘要： A compound of formula (I): wherein all symbols have the same meanings as defined in the specification; a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug thereof, has an Itk inhibitory activity, and is useful as a method for preventing and/or treating atopic dermatitis, and the like.
摘要翻译：式（I）的化合物：其中所有符号具有与说明书中定义的相同的含义; 其盐，其溶剂合物，N-氧化物或其前药具有Itk抑制活性，可用作预防和/或治疗特应性皮炎等的方法。

8. 发明授权

US10264976B2 Biocompatible flavonoid compounds for organelle and cell imaging 有权
公开(公告)号：US10264976B2
公开(公告)日：2019-04-23
申请号：US14934665
申请日：2015-11-06
申请人： Yi Pang , Bin Liu
发明人： Yi Pang , Bin Liu
IPC分类号： A61B5/00 , A61K49/00 , C07D311/30 , C12N15/113 , C07F9/6533 , C12Q1/02 , G01N33/58 , A61K31/713
摘要： Flavonoid compounds may be prepared that are selective for certain cell organelles, and may be used as biological imaging agents. Organelles that may be imaged with flavonoid compounds include mitochondria and lysosomes. Advantageously, the flavonoids show specificity to certain organelles and may exhibit a florescence “turn-on” mechanism, where the flavonoids that have target an organelle exhibit a florescence response when excited.

9. 发明授权

US09590099B2 Semiconductor devices having gate structures and methods of manufacturing the same 有权
标题翻译：具有栅极结构的半导体器件及其制造方法
公开(公告)号：US09590099B2
公开(公告)日：2017-03-07
申请号：US14859447
申请日：2015-09-21
申请人： Bin Liu , Sun-Min Kim , Shigenobu Maeda
发明人： Bin Liu , Sun-Min Kim , Shigenobu Maeda
IPC分类号： H01L29/66 , H01L29/78 , H01L29/08 , H01L29/161 , H01L29/167 , H01L29/423 , H01L29/51 , H01L29/786 , H01L29/10 , H01L29/06 , H01L21/324
CPC分类号： H01L29/7833 , H01L21/324 , H01L29/0649 , H01L29/0847 , H01L29/1054 , H01L29/161 , H01L29/167 , H01L29/42364 , H01L29/513 , H01L29/66545 , H01L29/785 , H01L29/78684 , H01L29/78696
摘要： Semiconductor devices are provided including an active layer, a gate structure, a spacer, and a source/drain layer. The active layer is on the substrate and includes germanium. The active layer includes a first region having a first germanium concentration, and a second region on both sides of the first region. The second region has a top surface getting higher from a first portion of the second region adjacent to the first region toward a second portion of the second region far from the first region, and has a second germanium concentration less than the first germanium concentration. The gate structure is formed on the first region of the active layer. The spacer is formed on the second region of the active layer, and contacts a sidewall of the gate structure. The source/drain layer is adjacent to the second region of the active layer.
摘要翻译：提供了包括有源层，栅极结构，间隔物和源极/漏极层的半导体器件。有源层在基底上，包括锗。有源层包括具有第一锗浓度的第一区域和位于第一区域两侧的第二区域。第二区域具有从与第一区域相邻的第二区域的第一部分朝向远离第一区域的第二区域的第二部分更高的顶表面，并且具有小于第一锗浓度的第二锗浓度。栅极结构形成在有源层的第一区域上。间隔物形成在有源层的第二区域上，并与门结构的侧壁接触。源极/漏极层与有源层的第二区域相邻。

10. 发明申请

US20160129773A1 VEHICLE SHADING APPARATUS 审中-公开
标题翻译：车辆遮光装置
公开(公告)号：US20160129773A1
公开(公告)日：2016-05-12
申请号：US14538287
申请日：2014-11-11
申请人： Bin Liu
发明人： Bin Liu
IPC分类号： B60J11/02
CPC分类号： B60J11/02
摘要： A vehicle shading apparatus may include a first front shading control unit, a first rear shading control unit, a second top shading control unit, and a second rear shading control unit. In one embodiment, one end of the first top shading control unit is connected to the second top shading control unit. One end of the first rear shading control unit and a horizontal supporting unit are connected to the second rear shading control unit. The second top shading control unit and second rear shading control unit both include a shading cloth extending along the body of the vehicle. The present invention is advantageous because it has an automatic shading cloth expand/restore control unit and high-strength supporting unit. It is portable, easy to install and has the shading all around the vehicle to effectively block the sunlight.
摘要翻译：车辆遮光装置可以包括第一前遮光控制单元，第一后遮光控制单元，第二顶部遮光控制单元和第二后遮光控制单元。在一个实施例中，第一顶部遮光控制单元的一端连接到第二顶部遮光控制单元。第一后遮光控制单元的一端和水平支撑单元连接到第二后遮光控制单元。第二顶部遮光控制单元和第二后遮光控制单元都包括沿车体延伸的遮光布。本发明是有利的，因为它具有自动遮光布扩/恢复控制单元和高强度支撑单元。它是便携式的，易于安装，并且在车辆周围具有阴影，以有效地阻挡阳光。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式